Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Completed · Phase 2 · Has a placebo group
Conditions studied: Severe Acute Respiratory Syndrome
In brief
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Key facts
- Study ID
- NCT04470544
- Run by
- Alan Bryce
- People needed
- 100
- Starts
- 2020-07-28
- Expected to finish
- 2022-01-20
- Last updated by the study team
- 2024-11-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Laboratory confirmed SARS-CoV-2 infection
- Admitted to hospital for management of SARS-CoV-2
- Age ≥18
- Subject or legal representative able to give informed consent
- Ability to take all study drugs
- Respiratory status of 3 or greater on the WHO ordinal scale
- ALT or AST ≤5 x ULN
- Creatinine clearance ≥50 mL/min using the Cockroft-Gault formula
- Willingness to provide mandatory specimens for correlative research and banking
You may not qualify if…
- Women who are pregnant or breastfeeding
- Known hypersensitivity to the study drug, the metabolites or formulation excipient
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States
- Tucson Medical Center — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.